🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2025-524056-63-00
Completed Phase I

​​AMG 436 as monotherapy and combination therapy in participants with Microsatellite Instability-High/Mismatch Repair Deficient Solid Tumors ​

2025-524056-63-00 · tracked via the Priya Life Science EU tracker
Sponsor
Amgen Inc.
Sponsor type
Pharmaceutical company
Therapeutic area
Neoplasms
Decision date
28/04/2026
Enrollment target
77
Sites
Spain, France, Belgium

Condition studied

microsatellite instability high/mismatch repair deficient (MSI-H/dMMR) solid tumors

Eligibility

Age group
18-64 years, 65+ years
Sex
Female, Male
Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-524056-63-00 on CTIS ↗ ← All trials in the EU